Researchers Jonathan E. Knikman

Jonathan E. Knikman

Assistant Professor

Biography

Jonathan Knikman, PhD, PharmD, Clinical Pharmacologist, works as an assistant professor at the Julius Center for Health Sciences & Primary Care, Department of Public Global Health & Bioethics. Trained as a pharmacist, clinical pharmacologist, a PhD in clinical pharmacology and precision medicine, and currently pursuing a masters in (clinical) epidemiology, his current work focuses on the personalised medicine of antihypertensive drugs.

Jonathan Knikman ensures the scientific coordination of the clinical trial (WP5) in the Hypermarker project, focused on personalised pharmacometabolomic optimisation of treatment for hypertension. Furthermore, he is also involved in the study of the influence of nutrition on the effectiveness on antihypertension drugs (WP3) and the prediction of response to antihypertensive drugs (WP4).

Contact

jknikman@umcutrecht.nl

Pure profile

Recent publications

All publications

Severe fluoropyrimidine toxicity in older adults with cancer with DPYD wild type Edwin Brokaar, Jonathan Knikman, Loes Visser, Frederiek van den Bos, Linda Henricks, Carin Lunenburg, Femke de Man, Hans Gelderblom, Jan Schellens, Ron Mathijssen, Henk-Jan Guchelaar, Johanneke Portielje, Annemieke Cats, Wout Postmus, Nienke de Glas
Fundamental and Clinical Pharmacology, 2025, vol. 39

A Nomogram to Predict Severe Toxicity in DPYD Wild-Type Patients Treated With Capecitabine-Based Anticancer Regimens Jonathan E Knikman, Marta Lopez-Yurda, Didier Meulendijks, Maarten J Deenen, Jan H M Schellens, Jos Beijnen, Annemieke Cats, Henk-Jan Guchelaar
Clinical Pharmacology and Therapeutics, 2024, vol. 115, p.269-277

Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD Jonathan E. Knikman, Qinglian Zhai, Carin A.T.C. Lunenburg, Linda M. Henricks, Stefan Böhringer, Maaike van der Lee, Femke M. de Man, Steven M. Offer, Shikshya Shrestha, Geert Jan Creemers, Arnold Baars, Vincent O. Dezentjé, Alexander L.T. Imholz, Frank J.F. Jeurissen, Johanna E.A. Portielje, Rob L.H. Jansen, Paul Hamberg, Helga J. Droogendijk, Miriam Koopman, Peter Nieboer, Marlène H.W. van de Poel, Caroline M.P.W. Mandigers, Ron H.N. van Schaik, Hans Gelderblom, Ron H.J. Mathijssen, Jan H.M. Schellens, Annemieke Cats, Henk Jan Guchelaar, Jesse J. Swen
Genome Medicine, 2024, vol. 16

Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis Jonathan E Knikman, Tycho A Wilting, Marta Lopez-Yurda, Linda M Henricks, Carin A T C Lunenburg, Femke M de Man, Didier Meulendijks, Peter Nieboer, Helga J Droogendijk, Geert-Jan Creemers, Caroline M P W Mandigers, Alexander L T Imholz, Ron H J Mathijssen, Johanneke E A Portielje, Liselot Valkenburg-van Iersel, Annelie Vulink, Marlene H W van der Poel, Arnold Baars, Jesse J Swen, Hans Gelderblom, Jan H M Schellens, Jos H Beijnen, Henk-Jan Guchelaar, Annemieke Cats
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, vol. 41, p.5411-5421

Development of a UPLC-MS/MS Assay for the Quantitative Determination of Capecitabine, 5'-deoxy-5-fluorocytidine (5'-dFCR), 5'-deoxy-5-fluorouridine (5'-dFUR), 5'-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL) J E Knikman, Niels de Vries, H Rosing, A Cats, H-J Guchelaar, J H Beijnen
Pharmazie, 2023, vol. 78, p.107-112

Assay performance and stability of uracil and dihydrouracil in clinical practice Jonathan E Knikman, Hilde Rosing, Henk-Jan Guchelaar, Annemieke Cats, Jos H Beijnen
Cancer Chemotherapy and Pharmacology, 2023, vol. 91, p.257-266